Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response

Editors:

ISBN: 978-1-58829-646-7 (Print) 978-1-60327-088-5 (Online)

Table of contents (21 chapters)

previous Page of 2
  1. Front Matter

    Pages i-xiv

  2. Genomic Experimental Approaches in Oncology

    1. Front Matter

      Pages 1-1

    2. No Access

      Book Chapter

      Pages 3-18

      Toward the Realization of the Promise of Microarrays in Oncology

    3. No Access

      Book Chapter

      Pages 19-31

      Cell-Based Models to Identify Genetic Variants Contributing to Anticancer Drug Response

    4. No Access

      Book Chapter

      Pages 33-45

      Proteomic Analysis in Cancer Patients

    5. No Access

      Book Chapter

      Pages 47-56

      MicroRNAs and Discovery of New Targets

    6. No Access

      Book Chapter

      Pages 57-74

      Pharmacogenomics of the National Cancer Institute’s 60-Tumor Cell Panel

    7. No Access

      Book Chapter

      Pages 75-88

      Use of Single-Nucleotide Polymorphism Array for Tumor Aberrations in Gene Copy Numbers

  3. Pharmacogenomics of Toxicity and Response of Chemotherapy

    1. Front Matter

      Pages 90-90

    2. No Access

      Book Chapter

      Pages 91-101

      Concordance Between Tumor and Germline DNA

    3. No Access

      Book Chapter

      Pages 103-126

      Epidermal Growth Factor Receptor Mutations and Sensitivity to Selective Kinase Inhibitors in Human Lung Cancer

    4. No Access

      Book Chapter

      Pages 127-150

      BCR-ABL Mutations and Imatinib Resistance in Chronic Myeloid Leukemia Patients

    5. No Access

      Book Chapter

      Pages 151-172

      Role of Thymidylate Synthase Gene Variations in Colorectal Cancer Patients

    6. No Access

      Book Chapter

      Pages 173-201

      Thiopurines in the Treatment of Childhood Acute Lymphoblastic Leukemia and Genetic Variants of the Thiopurine S-Methyltransferase Gene

    7. No Access

      Book Chapter

      Pages 203-229

      Impact of Polymorphisms on the Clinical Outcomes of Monoclonal Antibody Therapy Against Hematologic Malignancies

    8. No Access

      Book Chapter

      Pages 231-247

      DNA Repair and Mitotic Checkpoint Genes as Potential Predictors of Chemotherapy Response in Non-Small-Cell Lung Cancer

    9. No Access

      Book Chapter

      Pages 249-265

      Dihydropyrimidine Dehydrogenase (Dpyd) Gene Polymorphism: Portrait of a Serial Killer

    10. No Access

      Book Chapter

      Pages 267-286

      Impact of UDP-Glucuronosyltransferase 1A Haplotypes on Irinotecan Treatment

    11. No Access

      Book Chapter

      Pages 287-298

      Microarray Profiling in Breast Cancer Patients

    12. No Access

      Book Chapter

      Pages 299-310

      Role of the Folate-Pathway and the Thymidylate Synthase Genes in Pediatric Acute Lymphoblastic Leukemia Treatment Response

  4. Pharmacogenomics in Clinical Drug Development in Oncology

    1. Front Matter

      Pages 311-311

    2. No Access

      Book Chapter

      Pages 313-325

      Pharmacogenomics in Drug Development: A Pharmaceutical Industry Perspective

    3. No Access

      Book Chapter

      Pages 327-338

      Identification of Pharmacogenomic Biomarker Classifiers in Cancer Drug Development

    4. No Access

      Book Chapter

      Pages 339-351

      Toxicogenomics Application to Oncology Drug Development

  5. Back Matter

    Pages 371-377

previous Page of 2